EA200000815A1 - SALT PAROXETINE - Google Patents

SALT PAROXETINE

Info

Publication number
EA200000815A1
EA200000815A1 EA200000815A EA200000815A EA200000815A1 EA 200000815 A1 EA200000815 A1 EA 200000815A1 EA 200000815 A EA200000815 A EA 200000815A EA 200000815 A EA200000815 A EA 200000815A EA 200000815 A1 EA200000815 A1 EA 200000815A1
Authority
EA
Eurasian Patent Office
Prior art keywords
paroxetine
salt
methylbenzenesulfonic
hypophosphorous
glutamic
Prior art date
Application number
EA200000815A
Other languages
Russian (ru)
Inventor
Дэвид Кроуэ
Дейрдр О'Кифф
Майкл Уркухарт
Original Assignee
Смитклайн Бичам Плс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9802665.1A external-priority patent/GB9802665D0/en
Priority claimed from GBGB9802640.4A external-priority patent/GB9802640D0/en
Priority claimed from GBGB9802656.0A external-priority patent/GB9802656D0/en
Priority claimed from GBGB9802659.4A external-priority patent/GB9802659D0/en
Priority claimed from GBGB9802644.6A external-priority patent/GB9802644D0/en
Priority claimed from GBGB9802664.4A external-priority patent/GB9802664D0/en
Priority claimed from GBGB9802653.7A external-priority patent/GB9802653D0/en
Priority claimed from GBGB9802646.1A external-priority patent/GB9802646D0/en
Priority claimed from GBGB9802661.0A external-priority patent/GB9802661D0/en
Priority claimed from GBGB9802658.6A external-priority patent/GB9802658D0/en
Priority claimed from GBGB9802657.8A external-priority patent/GB9802657D0/en
Priority claimed from GBGB9802638.8A external-priority patent/GB9802638D0/en
Priority claimed from GBGB9802639.6A external-priority patent/GB9802639D0/en
Priority claimed from GBGB9802698.2A external-priority patent/GB9802698D0/en
Priority claimed from GBGB9802645.3A external-priority patent/GB9802645D0/en
Priority claimed from GBGB9802654.5A external-priority patent/GB9802654D0/en
Priority claimed from GBGB9802655.2A external-priority patent/GB9802655D0/en
Priority claimed from GBGB9817359.4A external-priority patent/GB9817359D0/en
Priority claimed from GBGB9817309.9A external-priority patent/GB9817309D0/en
Priority claimed from GBGB9817307.3A external-priority patent/GB9817307D0/en
Priority claimed from GBGB9817340.4A external-priority patent/GB9817340D0/en
Priority claimed from GBGB9817344.6A external-priority patent/GB9817344D0/en
Priority claimed from GBGB9817321.4A external-priority patent/GB9817321D0/en
Priority claimed from GBGB9817360.2A external-priority patent/GB9817360D0/en
Priority claimed from GBGB9817317.2A external-priority patent/GB9817317D0/en
Priority claimed from GBGB9817364.4A external-priority patent/GB9817364D0/en
Priority claimed from GBGB9817320.6A external-priority patent/GB9817320D0/en
Priority claimed from GBGB9817322.2A external-priority patent/GB9817322D0/en
Priority claimed from GBGB9826173.8A external-priority patent/GB9826173D0/en
Priority claimed from GBGB9826172.0A external-priority patent/GB9826172D0/en
Priority claimed from GBGB9827341.0A external-priority patent/GB9827341D0/en
Priority claimed from GBGB9827277.6A external-priority patent/GB9827277D0/en
Priority claimed from GBGB9828775.8A external-priority patent/GB9828775D0/en
Application filed by Смитклайн Бичам Плс filed Critical Смитклайн Бичам Плс
Publication of EA200000815A1 publication Critical patent/EA200000815A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Соль пароксетина с кислотой, выбранной из группы, состоящей из серной, винной, щавелевой, фумаровой, пропионовой, муравьиной, глутаминовой, янтарной, бензойной, лимонной, азотной, фосфорной, 4-метилбензолсульфоновой, фосфорноватистой, молочной и миндальной кислот и глицина, полезная при лечении и профилактике некоторых нарушений центральной нервной системы.Международная заявка была опубликована вместе с отчетом о международном поиске.The salt of paroxetine with an acid selected from the group consisting of sulfuric, tartaric, oxalic, fumaric, propionic, formic, glutamic, succinic, benzoic, citric, nitric, phosphoric, 4-methylbenzenesulfonic, hypophosphorous, lactic, and mandelic acids and glycine, useful when treatment and prevention of certain central nervous system disorders. The international application was published along with an international search report.

EA200000815A 1998-02-06 1999-02-05 SALT PAROXETINE EA200000815A1 (en)

Applications Claiming Priority (34)

Application Number Priority Date Filing Date Title
GBGB9802656.0A GB9802656D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802640.4A GB9802640D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802644.6A GB9802644D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802655.2A GB9802655D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802653.7A GB9802653D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802646.1A GB9802646D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802661.0A GB9802661D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802658.6A GB9802658D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802657.8A GB9802657D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802638.8A GB9802638D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802639.6A GB9802639D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802698.2A GB9802698D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802645.3A GB9802645D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802654.5A GB9802654D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802665.1A GB9802665D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802659.4A GB9802659D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802664.4A GB9802664D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9817307.3A GB9817307D0 (en) 1998-08-08 1998-08-08 Novel compound
GBGB9817340.4A GB9817340D0 (en) 1998-08-08 1998-08-08 Novel compounds
GBGB9817344.6A GB9817344D0 (en) 1998-08-08 1998-08-08 Novel compounds
GBGB9817321.4A GB9817321D0 (en) 1998-08-08 1998-08-08 Novel compound
GBGB9817360.2A GB9817360D0 (en) 1998-08-08 1998-08-08 Novel compounds
GBGB9817309.9A GB9817309D0 (en) 1998-08-08 1998-08-08 Novel compounds
GBGB9817317.2A GB9817317D0 (en) 1998-08-08 1998-08-08 Novel compounds
GBGB9817364.4A GB9817364D0 (en) 1998-08-08 1998-08-08 Novel compounds
GBGB9817359.4A GB9817359D0 (en) 1998-08-08 1998-08-08 Novel compounds
GBGB9817322.2A GB9817322D0 (en) 1998-08-10 1998-08-10 Novel compounds
GBGB9817320.6A GB9817320D0 (en) 1998-08-10 1998-08-10 Novel compounds
GBGB9826173.8A GB9826173D0 (en) 1998-11-30 1998-11-30 Novel compounds
GBGB9826172.0A GB9826172D0 (en) 1998-11-30 1998-11-30 Novel compound
GBGB9827341.0A GB9827341D0 (en) 1998-12-11 1998-12-11 Novel compounds
GBGB9827277.6A GB9827277D0 (en) 1998-12-11 1998-12-11 Novel compound
GBGB9828775.8A GB9828775D0 (en) 1998-12-29 1998-12-29 Novel compounds
PCT/GB1999/000380 WO1999040084A1 (en) 1998-02-06 1999-02-05 Salts of paroxetine

Publications (1)

Publication Number Publication Date
EA200000815A1 true EA200000815A1 (en) 2001-02-26

Family

ID=27586915

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000815A EA200000815A1 (en) 1998-02-06 1999-02-05 SALT PAROXETINE

Country Status (11)

Country Link
EP (1) EP1053234A1 (en)
JP (1) JP2002505254A (en)
KR (1) KR20010040711A (en)
BG (1) BG104737A (en)
CA (1) CA2319652A1 (en)
EA (1) EA200000815A1 (en)
IL (1) IL137684A0 (en)
NO (1) NO20003960L (en)
PL (1) PL342295A1 (en)
SK (1) SK11812000A3 (en)
WO (1) WO1999040084A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH689805A8 (en) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Paroxetine methanesulfonate, process for its preparation and pharmaceutical compositions containing it.
GB9814316D0 (en) * 1998-07-02 1998-09-02 Smithkline Beecham Plc Novel compounds
WO2000008016A1 (en) * 1998-08-08 2000-02-17 Smithkline Beecham Plc Paroxetine salts
GB9827431D0 (en) * 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel compound
WO2000078290A2 (en) * 1999-06-22 2000-12-28 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a salt of paroxetine
HU226912B1 (en) * 2000-04-07 2010-03-01 Richter Gedeon Nyrt New paroxetin salt and medicament containing it
KR20030066797A (en) * 2001-01-05 2003-08-09 일라이 릴리 앤드 캄파니 Excitatory amino acid receptor antagonists
EP1412350A1 (en) * 2001-08-02 2004-04-28 Spurcourt Limited Paroxetine isethionate salt, process of preparation and use in the treatment of depression
KR100672184B1 (en) 2004-09-21 2007-01-19 주식회사종근당 Paroxetine cholate or cholic acid derivative salts
CN108218844B (en) * 2018-03-08 2021-01-19 合肥科大生物技术有限公司 Memantine paroxetine eutectic salt and preparation method, pharmaceutical composition and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
ES2058061T3 (en) * 1985-10-25 1994-11-01 Beecham Group Plc DERIVED FROM PIPERIDINE, ITS PREPARATION AND ITS USE AS A MEDICINAL PRODUCT.
CA2206592A1 (en) * 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride
HU221921B1 (en) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzyl-piperidine or tetrahydro-pyridine derivatives and processes for producing them

Also Published As

Publication number Publication date
JP2002505254A (en) 2002-02-19
IL137684A0 (en) 2001-10-31
SK11812000A3 (en) 2001-08-06
EP1053234A1 (en) 2000-11-22
WO1999040084A1 (en) 1999-08-12
NO20003960D0 (en) 2000-08-04
CA2319652A1 (en) 1999-08-12
KR20010040711A (en) 2001-05-15
BG104737A (en) 2001-07-31
PL342295A1 (en) 2001-06-04
NO20003960L (en) 2000-09-25

Similar Documents

Publication Publication Date Title
EA200000815A1 (en) SALT PAROXETINE
DE69912151D1 (en) CARBOXYLIC ACIDS AND CARBOXYLIC ACID ISOSTERES OF N-HETEROCYCLIC COMPOUNDS
DE69711034D1 (en) AQUEOUS FLUOROPOLYMER SOLUTIONS FOR TREATING HARD SURFACES
DK1619249T3 (en) Induction of exon skipping in eukaryotic cells
EA200000349A1 (en) METHOD OF TREATMENT OF OPPOSITIONAL DISORDERS
EA199800798A1 (en) NEW MIXED CYCLIC AMINO ACIDS AS PHARMACEUTICAL AGENTS
EA200001244A1 (en) COMBINATION THERAPY FOR THE TREATMENT OF BIPOLAR DISORDERS
DE69736249D1 (en) TREATMENT OF PAIN
EA200300807A1 (en) TREATMENT OF CENTRAL NERVOUS SYSTEM DISTURBANCES USING D-AMINO ACID AND D-ASPARTOTOXIDASE OXIDASE ANTAGONISTS
MX291457B (en) Methods for producing enantiomerically pure alpha-substituted carboxylic acids.
DE60115954D1 (en) PROCESS FOR THE PREPARATION OF GABAPENTIN
ATE225171T1 (en) AMINO ACID DERIVATIVES FOR THE TREATMENT OF STROKE
IL157495A0 (en) Method for the production of d-panthothenic acid and/or salts thereof as adjunct for animal feedstuffs
ATE294584T1 (en) USE OF DESOXYPEGANINE TO TREAT ALZHEIMER'S DEMENTIA
DE69827163D1 (en) PHYTASE FOR PREVENTING OR TREATING MASTITIS
ATE409469T1 (en) USE OF 2,2,3,3, TETRAMETHYLCYCLOPROPANE CARBOXIC ACID DERIVATIVES FOR THE TREATMENT OF PSYCHIATRIC DISORDERS
ATE345818T1 (en) S-METHYL-DIHYDRO-ZIPRASIDONE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS.
DE69724563D1 (en) Process for the preparation of N-hydrocarbyl substituted amides
AP2000001879A0 (en) Salts of paroxetine.
ATE349544T1 (en) METHOD FOR PRODUCING D-PANTOTHENIC ACID AND/OR SALTS THEREOF AS AN ADDITIVE TO ANIMAL FEED
ATE498692T1 (en) METHOD FOR DETERMINING ORNITHINE DECARBOXYLASE ACTIVITY AND FOR IDENTIFYING EFFECTORS OF ORNITHINE DECARBOXYLASE ACTIVITY
BR9907632A (en) Paroxetine salts
NL1014511A1 (en) Production of lactic acid bacteria without amino acid decarboxylating activity.
SE9801726D0 (en) New process
DE60026848D1 (en) C-6 RING-ASSOCIATED PYRIDOA1,2-ABOVE-ZIMIDAZOLE DERIVATIVES FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM